HRP20120738T1 - Inhibitori kinaza akt i p70 s6 - Google Patents

Inhibitori kinaza akt i p70 s6 Download PDF

Info

Publication number
HRP20120738T1
HRP20120738T1 HRP20120738AT HRP20120738T HRP20120738T1 HR P20120738 T1 HRP20120738 T1 HR P20120738T1 HR P20120738A T HRP20120738A T HR P20120738AT HR P20120738 T HRP20120738 T HR P20120738T HR P20120738 T1 HRP20120738 T1 HR P20120738T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
attached
independently
Prior art date
Application number
HRP20120738AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120738T1 publication Critical patent/HRP20120738T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20120738AT 2008-11-11 2009-11-03 Inhibitori kinaza akt i p70 s6 HRP20120738T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20120738T1 true HRP20120738T1 (hr) 2012-10-31

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120738AT HRP20120738T1 (hr) 2008-11-11 2009-11-03 Inhibitori kinaza akt i p70 s6

Country Status (36)

Country Link
US (1) US8148387B2 (2)
EP (1) EP2358710B1 (2)
JP (1) JP5432275B2 (2)
KR (1) KR101334460B1 (2)
CN (1) CN102216302B (2)
AR (1) AR074072A1 (2)
AU (1) AU2009314324B2 (2)
BR (1) BRPI0921916A2 (2)
CA (1) CA2743019C (2)
CO (1) CO6382114A2 (2)
CR (1) CR20110240A (2)
CY (1) CY1113409T1 (2)
DK (1) DK2358710T3 (2)
DO (1) DOP2011000129A (2)
EA (1) EA018947B1 (2)
EC (1) ECSP11011048A (2)
ES (1) ES2391704T3 (2)
HN (1) HN2011001247A (2)
HR (1) HRP20120738T1 (2)
IL (1) IL211940A (2)
JO (1) JO2822B1 (2)
MA (1) MA32776B1 (2)
MX (1) MX2011005000A (2)
MY (1) MY161461A (2)
NZ (1) NZ592062A (2)
PA (1) PA8846901A1 (2)
PE (1) PE20110807A1 (2)
PL (1) PL2358710T3 (2)
PT (1) PT2358710E (2)
RS (1) RS52520B (2)
SI (1) SI2358710T1 (2)
TN (1) TN2011000207A1 (2)
TW (1) TWI422587B (2)
UA (1) UA100190C2 (2)
WO (1) WO2010056563A1 (2)
ZA (1) ZA201102549B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201402867TA (en) 2009-07-02 2014-08-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
PT2755965T (pt) 2011-09-12 2017-11-02 Merck Patent Gmbh Novas imidazol aminas como moduladores da atividade quinase
US9321760B2 (en) 2011-09-12 2016-04-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
EP2920154B1 (en) 2012-11-16 2017-10-11 Merck Patent GmbH Novel imidazol-piperidinyl derivatives as modulators of kinase activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
AR095202A1 (es) * 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
MX2016010268A (es) * 2014-02-11 2016-10-13 Merck Patent Gmbh Pirimidinimidazolaminas como modulares de actividad de cinasa.
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
PT3459953T (pt) 2016-05-20 2021-07-29 Taiho Pharmaceutical Co Ltd Novo derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona
CN115397815B (zh) * 2020-03-17 2024-06-14 江苏恒瑞医药股份有限公司 稠合二环类衍生物、其制备方法及其在医药上的应用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2024535857A (ja) 2021-09-17 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
WO2024009977A1 (ja) * 2022-07-05 2024-01-11 大鵬薬品工業株式会社 ５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン及びその塩体の結晶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
ECSP11011048A (es) 2011-06-30
WO2010056563A1 (en) 2010-05-20
US20100120801A1 (en) 2010-05-13
MY161461A (en) 2017-04-14
IL211940A0 (en) 2011-06-30
CY1113409T1 (el) 2016-06-22
EA201170680A1 (ru) 2011-12-30
SI2358710T1 (sl) 2012-11-30
JP2012508274A (ja) 2012-04-05
RS52520B (sr) 2013-04-30
DK2358710T3 (da) 2012-09-03
HN2011001247A (es) 2013-05-20
MA32776B1 (fr) 2011-11-01
DOP2011000129A (es) 2016-02-29
KR101334460B1 (ko) 2013-12-02
IL211940A (en) 2014-01-30
BRPI0921916A2 (pt) 2015-12-29
NZ592062A (en) 2013-03-28
TN2011000207A1 (en) 2012-12-17
PT2358710E (pt) 2012-10-01
CO6382114A2 (es) 2012-02-15
EP2358710B1 (en) 2012-08-15
AU2009314324A1 (en) 2010-05-20
EA018947B1 (ru) 2013-11-29
JP5432275B2 (ja) 2014-03-05
EP2358710A1 (en) 2011-08-24
CR20110240A (es) 2011-06-09
KR20110074578A (ko) 2011-06-30
ES2391704T3 (es) 2012-11-29
PL2358710T3 (pl) 2012-12-31
MX2011005000A (es) 2011-05-25
TW201022268A (en) 2010-06-16
TWI422587B (zh) 2014-01-11
CA2743019A1 (en) 2010-05-20
US8148387B2 (en) 2012-04-03
CN102216302B (zh) 2013-08-21
ZA201102549B (en) 2012-09-26
CN102216302A (zh) 2011-10-12
PA8846901A1 (es) 2010-06-28
AR074072A1 (es) 2010-12-22
PE20110807A1 (es) 2011-10-31
CA2743019C (en) 2013-08-13
JO2822B1 (en) 2014-09-15
HK1158203A1 (en) 2012-07-13
UA100190C2 (en) 2012-11-26
AU2009314324B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
JP2012508274A5 (2)
TW200716645A (en) Macrocyclic heterocyclic aspartyl protease inhibitors
NZ602141A (en) Inhibitors of semicarabazide-sensitive amine oxidase
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
NI200600262A (es) 4-fenilamino-quinazolin-6-il-amidas.
MY138941A (en) Aryl-pyridine derivatives
MX2010005824A (es) Derivados de aminotiazol.
NZ603364A (en) Inhibitors of arginase and their therapeutic applications
RU2012136643A (ru) [5,6]- гетероциклическое соединение
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
TN2011000611A1 (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
JO2972B1 (en) Piperidine / piperazine derivatives
MX2018005239A (es) Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f][1,2,4]triazinona como inhibidores de fosfodiesterasa y sus usos.
TW200745032A (en) Novel heterobicyclic derivatives
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni